BioAtla Inc [BCAB] stock prices are up 9.89% to $0.45 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCAB shares have gain 19.05% over the last week, with a monthly amount glided 28.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on August 13, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, H.C. Wainwright downgraded its rating to Neutral on November 13, 2024. On September 15, 2022, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $17 on the stock. Credit Suisse downgraded its rating to a Neutral and decreased its price target to $5 on May 05, 2022. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on March 21, 2022. In a note dated June 28, 2021, ROTH Capital initiated an Buy rating and provided a target price of $75 on this stock.
The stock price of BioAtla Inc [BCAB] has been fluctuating between $0.24 and $2.53 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. BioAtla Inc [NASDAQ: BCAB] shares were valued at $0.45 at the most recent close of the market. An investor can expect a potential return of 1011.11% based on the average BCAB price forecast.
Analyzing the BCAB fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -5.8%, Pretax Profit Margin comes in at -5.41%, and Net Profit Margin reading is -5.41%. To continue investigating profitability, this company’s Return on Assets is posted at -2.19, Equity is -11.32 and Total Capital is -6.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4119 points at the first support level, and at 0.3771 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4697, and for the 2nd resistance point, it is at 0.4927.
Ratios To Look Out For
It’s worth pointing out that BioAtla Inc [NASDAQ:BCAB]’s Current Ratio is 1.24. Further, the Quick Ratio stands at 1.24, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 2.39.
